Resveratrol-induced biochemical improvements in rats with hepatocellular carcinoma caused by diethylnitrosamine/carbon tetrachloride

Hepatocellular carcinoma (HCC) is one of the most prevalent causes of cancer-related death. This study attempted to investigate the impact of resveratrol (RSV) against HCC. Rats were classified into three groups. Group I (Normal control group). Group II (Diethylnitrosamine (DEN)/Carbon tetrachloride (CCL4) group): 200 mg of DEN per kg b.wt. i.p. was administered to rats once. 3 ml of CCL4 per kg b.wt. injected s.c. per week for six weeks, following two weeks of DEN application to enhance the carcinogenic impact. Group III (Resveratrol (RSV)- treated group): Rats with HCC were administered RSV at a dose of 100mg/kg body weight intraperitoneally for 4 weeks. DEN/CCL4 injection induced noticeable reduction in serum TP content and Alb level, hepatic SOD, CAT, and GSH-Px activities, along with an obvious increase in serum AST, ALT, and ALP activities and alpha fetoprotein (AFP) AFP level. Treatment with resveratrol in HCC-induced rats caused marked improvement in all biochemical parameters. According to the findings, resveratrol may be considered a promising option for treating hepatic cancer.